asa glp 1 agonists Perioperative management of patients taking glucagon-like peptide receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Perioperative Considerations for Patients on
Description
GLP-1 receptor agonists (GLP-1 RAs), already established in the management of type 2 diabetes mellitus and obesity, have emerged as promising candidates for the treatment of nonalcoholic steatohepatitis (NASH), owing to their broad metabolic and hepatoprotective effects
Shortly, other molecules such as liraglutide, dulaglutide, and semaglutide came forth, offering a once-weekly dosage
While these blends do not directly address receptor desensitization, they may support metabolic function during reset periods
Physiol Rev
